Serum marker analysis of Erlotinib treatment in previously treated Non-small cell lung cancer (NSCLC) patients with and without Epidermal Growth Factor Receptor (EGFR) mutation (additional study of CJLSG0903/0904)
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000005754
- Lead Sponsor
- Central Japan Lung Study Group (CJLSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 83
Not provided
1) Active infection or other serious disease condition (poorly controlled diabetes mellitus,cardiac disease,Unstable angina,Cardiac infarction, Psychological illness, etc.). 2) Pulmonary disorder(idiopathic pulmonary fibrosis,interstitial lung disease,pneumoconiosis,active radiation pneumonia,etc.). 3) Massive pleural effusion, pericardial effusion, ascites, and superior vena cava syndrome. 4) Symptomatic brain metastasis. 5) Severe drug allergy. 6) Previous radiotherapy to primary lung cancer. 7) Patients who have previously treated three or more chemotherapy. 8) Patients who had a relapse after surgery. 9) With active double cancer. 10) Pregnancy or lactation. 11) Severe disorder of the eye. 12) Patients whose participation in the trial is judged to be inappropriate by the attending doctor.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the correlation between the serum marker analysis and the clinical data such as response rate, disease control rate, overall survival and progression free survival for previously treated NSCLC patients with and without EGFR Mutation.
- Secondary Outcome Measures
Name Time Method To acquire the additional information on possible correlation between serum marker analysis and EGFR mutation status in previously treated NSCLC patients.